| nature.com webcasts |
| Practical Considerations for T Cell Receptor (TCR) Therapies Targeting Solid Tumors | ||
| Date: Tuesday, July 17, 2018 Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST |
||
| Register for FREE | ||
| This webcast has been produced on behalf of the sponsor who retains sole responsibility for content. About this content |
||
| About this webcast | ||
| T Cell Receptor (TCR)-transduced T cell therapies show great promise for targeting multiple solid tumor types, including gliomas. In this webcast the speakers we will provide an overview and discuss advantage of adoptive cells therapies targeting solid tumors via expression of tumor antigen specific TCRs. They will also cover a method for rapid cloning of functional TCRs targeting glioma specific mutant peptides using a digital cell biology platform, and demonstrate the advantages of automated cell cloning, culture and functional screening via a novel high throughput cell-cell interaction assay, resulting in the rapid validation of mutant antigen specific TCRs in a matter of weeks rather than months.
During this webcast you will learn/our speaker(s) will address:
|
||
| Unable to join the live event? Watch on demand — register now to ensure that you receive information on how to gain access after the live event.If you have already registered, we look forward to meeting you! |
||
| Speakers | ||
 Hideho Okada, MD, PhDDirector, Brain Tumor Immunotherapy Center in Neurological Surgery at University of California San Francisco Parker Institute for Cancer Immunotherapy |
||
 Dr. Christopher A. KlebanoffAssistant Member Memorial Sloan Kettering Cancer Center |
||
|
||